Imophoron
Imophoron is the developer of a novel next-generation rapid-response vaccine platform, ADDomer(TM).
Imophoron has raised €4.7M across 1 funding round from 3 investors, most recently a round in Oct 2021. Based in Bristol, UK; active in Healthtech. Data as of 28 Oct 2026.
Bristol, UK
Total raised
€4.7M
€4,711,980
Funding rounds
1
Investors
3
distinct backers
Active since
2021-10
latest 2021-10
Funding by year
EUR raised per yearImophoron — funding by year — interactive chart.
Data table
| Imophoron — funding by year | |
|---|---|
| 2021 | €4.7M |
Signals
High confidenceRaise-next likelihood6
base rate 30% for Other
- ▼ Dormant (no round in 3+ cohort gaps)
- ▼ Low backer re-investment
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2021-10-08 | Other | €4.7M | Dr Jonathan Milner,Octopus Ventures,Science Creates Ventures | View deal → |
Related news
- Imophoron Raises GBP 4M in Fundingfinsmes.com · 2021-10
Similar companies
same sector or countryGlobal coverage: FundingData